JQAD1

Overview

JQAD1 is a EP300 PROTAC degrader. JQAD1 selectively targets EP300 and induces its degradation via the CRBN -dependent proteasomal pathway. JQAD1 reduces the levels of H3K27ac and the expression of MYCN . JQAD1 induces apoptosis ( apoptosis ) and inhibits cancer cell growth. JQAD1 exerts anti-neuroblastoma effects in vivo in a CRBN -dependent manner. JQAD1 can be used for the research of neuroblastoma. (Pink: CBP/p300 ligand ( HY-107455 ); Blue: Cereblon ligand ( HY-W087383 ); Black: linker ( HY-W105740 )).

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Neuroblastoma | Products > Disease Areas > CNS Neoplasm | Products > Signaling Pathways > PROTAC | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Research Areas > Neurological Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > PARP | Products > Signaling Pathways > PROTACs | Products > Signaling Pathways > Histone Acetyltransferase | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Caspase

Product Information

• Catalog No.: HY-145765
• CAS No.: 2417097-18-6
• Molecular Formula: C48H52F4N6O9
• Molecular Weight: 932.95
• Purity: 98.24%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Availability: In-stock

Source

Original product source